Display options
Cite
Rodio DM, Anzivino E, Mischitelli M, et al. Increased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheumatic Diseases Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study. Front Microbiol. 2016;7:672doi: 10.3389/fmicb.2016.00672.
Rodio, D. M., Anzivino, E., Mischitelli, M., Bellizzi, A., Scrivo, R., Scribano, D., Conte, G., Prezioso, C., Trancassini, M., Valesini, G., Palamara, A. T., & Pietropaolo, V. (2016). Increased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheumatic Diseases Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study. Frontiers in microbiology, 7672. https://doi.org/10.3389/fmicb.2016.00672
Rodio, Donatella Maria, et al. "Increased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheumatic Diseases Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study." Frontiers in microbiology vol. 7 (2016): 672. doi: https://doi.org/10.3389/fmicb.2016.00672
Rodio DM, Anzivino E, Mischitelli M, Bellizzi A, Scrivo R, Scribano D, Conte G, Prezioso C, Trancassini M, Valesini G, Palamara AT, Pietropaolo V. Increased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheumatic Diseases Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study. Front Microbiol. 2016 May 10;7:672. doi: 10.3389/fmicb.2016.00672. eCollection 2016. PMID: 27242700; PMCID: PMC4861734.
Copy Download .nbib Format: NLM
Share it on

Front Microbiol. 2016 May 10;7:672. doi: 10.3389/fmicb.2016.00672. eCollection 2016.

Increased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheumatic Diseases Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study.

Frontiers in microbiology

Donatella Maria Rodio, Elena Anzivino, Monica Mischitelli, Anna Bellizzi, Rossana Scrivo, Daniela Scribano, Gianlorenzo Conte, Carla Prezioso, Maria Trancassini, Guido Valesini, Anna Teresa Palamara, Valeria Pietropaolo

Affiliations

  1. Department of Public Health and Infectious Diseases, "Sapienza" University of Rome Rome, Italy.
  2. Department of Public Health and Infectious Diseases, Institute Pasteur, Cenci-Bolognetti Foundation, "Sapienza" University of Rome Rome, Italy.
  3. Department of Internal Medicine and Medical Disciplines, Rheumatology, "Sapienza" University of Rome Rome, Italy.
  4. Department of Experimental and Clinical Sciences, "G. D'Annunzio" University of Chieti Chieti, Italy.
  5. Department of Public Health and Infectious Diseases, Institute Pasteur, Cenci-Bolognetti Foundation, "Sapienza" University of RomeRome, Italy; San Raffaele Pisana Scientific Institute for Research, Hospitalization and Health CareRome, Italy.
  6. Department of Public Health and Infectious Diseases, "Sapienza" University of RomeRome, Italy; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple UniversityPhiladelphia, PA, USA.

PMID: 27242700 PMCID: PMC4861734 DOI: 10.3389/fmicb.2016.00672

Abstract

Chronic inflammatory rheumatic diseases (CIRDs) are immune-mediated pathologies involving joints. To date, TNFα-blocking agents administration is the most promising therapy, although these treatments are associated with an increased Polyomavirus JC (JCPyV) reactivation, the etiological agent of the Progressive Multifocal Leukoencephalopathy (PML). The aim of this study was the recruitment and the analysis of a CIRDs cohort in order to investigate a possible correlation between JCPyV presence and the influence of anti-TNF-α agents on viral loads. Blood and urine samples were collected from 34 CIRDs subjects prior the first anti-TNF-α infusion (T0) and after 3 (T3), 6 (T6), 12 (T12), and 18 (T18) months. Results showed persistent JC viruria significantly higher than JC viremia throughout the 18 month follow-up study (p = 0.002). In JCPyV positive samples, the non-coding control region (NCCR) was analyzed. Results evidenced archetypal structures (type II-S) in all isolates with the exception of a sequence isolated from a plasma sample, that corresponds to the type II-R found in PML subjects. Finally, the viral protein 1 (VP1) genotyping was performed and results showed the prevalence of the European genotypes 1A, 1B, and 4. Since only few studies have been carried out to understand whether there is a PML risk in CIRDs population infected by JCPyV, this study contributes to enrich literature insight on JCPyV biology in this cluster. Further investigations are necessary in order to recognize the real impact of biologics on JCPyV life cycle and to identify possible and specific viral variants related to increased virulence in CIRDs patients.

Keywords: NCCR; VP1; anti-TNF-α; chronic inflammatory rheumatic diseases; human polyomavirus JC

References

  1. Lupus. 2013 Mar;22(3):307-11 - PubMed
  2. J Neurovirol. 2012 Feb;18(1):55-61 - PubMed
  3. J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1345-50 - PubMed
  4. Best Pract Res Clin Rheumatol. 2015 Apr;29(2):290-305 - PubMed
  5. Clin Microbiol Rev. 2012 Jul;25(3):471-506 - PubMed
  6. J Infect Dis. 2011 Jul 15;204(2):237-44 - PubMed
  7. J Neuroimmune Pharmacol. 2010 Sep;5(3):404-17 - PubMed
  8. J Med Virol. 2008 Dec;80(12):2147-52 - PubMed
  9. J Gen Virol. 2001 May;82(Pt 5):1221-331 - PubMed
  10. J Rheumatol. 1982 Sep-Oct;9(5):789-93 - PubMed
  11. Nurse Pract. 2015 Apr 13;40(4):40-6; quiz 46-7 - PubMed
  12. Ther Adv Neurol Disord. 2015 Nov;8(6):255-73 - PubMed
  13. Virol J. 2013 Sep 30;10:298 - PubMed
  14. J Med Virol. 2013 Apr;85(4):716-22 - PubMed
  15. JAMA Neurol. 2014 May;71(5):596-602 - PubMed
  16. Inflamm Bowel Dis. 2007 Jul;13(7):896-902 - PubMed
  17. Arthritis Rheum. 1984 Apr;27(4):361-8 - PubMed
  18. J Med Virol. 2013 Jul;85(7):1286-92 - PubMed
  19. Lancet Neurol. 2010 Apr;9(4):425-37 - PubMed
  20. Arch Virol. 2001;146(11):2097-113 - PubMed
  21. J Neurovirol. 2001 Aug;7(4):280-7 - PubMed
  22. J Med Virol. 1996 Jul;49(3):199-204 - PubMed
  23. J Cell Physiol. 2012 Dec;227(12):3796-802 - PubMed
  24. Best Pract Res Clin Rheumatol. 2006 Dec;20(6):1139-57 - PubMed
  25. Scand J Immunol. 1991 Dec;34(6):697-712 - PubMed
  26. J Neurovirol. 2003 Dec;9(6):603-11 - PubMed
  27. Rheumatology (Oxford). 2016 Apr;55(4):607-14 - PubMed
  28. J Gen Virol. 2010 Dec;91(Pt 12):3042-52 - PubMed
  29. World J Radiol. 2015 Sep 28;7(9):236-52 - PubMed
  30. Joint Bone Spine. 2015 Oct;82(5):375-6 - PubMed
  31. J Neurovirol. 2009 Jan;15(1):51-6 - PubMed
  32. J Neurovirol. 2011 Aug;17(4):303-13 - PubMed
  33. J Neurovirol. 2007 Aug;13(4):338-46 - PubMed
  34. BMC Med. 2012 Aug 01;10:82 - PubMed
  35. Arthritis Rheum. 1988 Mar;31(3):315-24 - PubMed
  36. APMIS. 2013 Aug;121(8):685-727 - PubMed
  37. Arthritis Rheum. 2012 Sep;64(9):3043-51 - PubMed
  38. Arthritis Care Res (Hoboken). 2012 Apr;64(4):612-5 - PubMed
  39. Semin Arthritis Rheum. 2015 Oct;45(2):163-6 - PubMed
  40. PLoS One. 2013 Dec 10;8(12):e82796 - PubMed
  41. Gut. 2008 Oct;57(10):1393-7 - PubMed
  42. Drug Saf. 2010 Nov 1;33(11):969-83 - PubMed
  43. J Gen Virol. 2012 Mar;93(Pt 3):651-61 - PubMed
  44. Clin Dev Immunol. 2013;2013:839719 - PubMed
  45. BMC Med. 2014 Mar 13;12:43 - PubMed
  46. Nature. 1989 May 18;339(6221):237-8 - PubMed
  47. J Infect Dis. 1993 Jan;167(1):13-20 - PubMed
  48. Rheumatology (Oxford). 2012 Jun;51 Suppl 4:iv9-13 - PubMed
  49. Neurologist. 2012 Mar;18(2):85-7 - PubMed
  50. Rheumatol Rehabil. 1973 Aug;12(3):115-34 - PubMed
  51. Arthritis Rheum. 2006 Aug;54(8):2665-73 - PubMed
  52. Virology. 1991 Feb;180(2):553-60 - PubMed
  53. Cytokine Growth Factor Rev. 2014 Feb;25(1):21-33 - PubMed
  54. J Infect Dis. 2009 Mar 15;199(6):837-46 - PubMed
  55. Med Microbiol Immunol. 2015 Oct;204(5):613-8 - PubMed
  56. J Virol. 1990 Jun;64(6):3139-43 - PubMed
  57. J Rheumatol. 1994 Dec;21(12):2286-91 - PubMed

Publication Types